#China #Hangzhou #ESG #MSCI #Tigermed

Tigermed Achieves MSCI ESG AAA Rating

Tigermed, a leading global provider of integrated research and development solutions in the biopharmaceutical and medical device industries, is excited to announce that it has been awarded the prestigious MSCI Environmental, Social, and Governance (ESG) AAA rating. This recognition is not just a badge of honor; it signifies Tigermed's commitment to integrating sustainability into its core business operations and stakeholder relations.

Significance of the MSCI ESG Rating

The MSCI ESG rating system is a widely recognized benchmark for assessing a company's environmental, social, and governance standards. A rating of AAA is the highest possible, indicating superior ESG performance. Companies achieving this score have demonstrated remarkable resilience to long-term risks and are often viewed as industry leaders in sustainable business practices.

Tigermed's journey to the AAA rating began with a concerted effort to embed ESG principles across all facets of its operations. The progression from a baseline rating to achieving AA in 2023 and now AAA exemplifies the company’s relentless pursuit of excellence in sustainability.

Environmental Commitment

Tigermed has established science-based targets for reducing its greenhouse gas emissions that have been validated by the Science Based Targets initiative (SBTi). The company employs a comprehensive environmental management system that includes improved monitoring of emissions and resource utilization. Additionally, Tigermed has embraced digital platforms and green office initiatives to drive environmental sustainability.

In 2024 alone, Tigermed made significant investments in employee training, totaling approximately 39.997 million yuan, which equates to an average of 99.48 training hours per employee. This commitment ensures that every team member is well-equipped to contribute positively to the company’s ESG goals.

Social Responsibility Efforts

On the social front, Tigermed has leveraged advanced technologies, including AI, to enhance the efficiency of clinical trials. The company prioritizes gender equality and workforce diversity, ensuring that all employees have equal opportunities to thrive. The Hangzhou Tigermed Foundation engages in public welfare initiatives addressing medical assistance, educational support, and poverty alleviation. Furthermore, it invests in rural revitalization efforts, aimed at reducing poverty through consumption-based initiatives.

Governance Enhancements

Strong corporate governance is at the heart of Tigermed's ESG framework. The company's board of directors diligently oversees all ESG-related matters, with the Compliance and ESG Committee led directly by the General Manager and managed by the Chief Compliance Officer. Notably, ESG performance metrics are integrated into the compensation structure for the General Manager, aligning leadership incentives with sustainable objectives.

To ensure a culture of compliance and ethical behavior, every employee undergoes comprehensive training in business ethics, and new suppliers are mandated to sign the Supplier Code of Conduct upon onboarding.

Future Aspirations

As Tigermed marks this significant milestone with its AAA MSCI ESG rating, the company acknowledges that this is just the beginning. It remains committed to refining its ESG governance framework, enhancing management systems, and driving sustainable growth. With a mantra of "Serving Innovation, Building Health Together," Tigermed seeks to create long-term value for its stakeholders while making meaningful contributions to global health and well-being.

The recognition from MSCI reaffirms Tigermed's position as a trailblazer in integrating sustainability into its business strategy and operations, setting an inspiring example for other organizations worldwide.

About Tigermed

Founded in 2003, Tigermed (Stock code 300347.SZ/3347.HK) has grown into a globally recognized entity, providing a range of integrated R&D solutions. With a portfolio that spans from preclinical development to clinical trials and commercialization, Tigermed collaborates with over 3,600 clients, aiding them in their development journeys efficiently and cost-effectively. Currently, the company operates a vast network of more than 180 locations and employs over 10,000 staff around the world. Learn more about Tigermed at www.tigermedgrp.com.